INFLARX NV (IFRX) Stock Price & Overview
NASDAQ:IFRX • NL0012661870
Current stock price
The current stock price of IFRX is 0.9672 USD. Today IFRX is up by 2.52%. In the past month the price increased by 1.68%. In the past year, price increased by 4.68%.
IFRX Key Statistics
- Market Cap
- 65.528M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -0.77
- Dividend Yield
- N/A
IFRX Stock Performance
IFRX Stock Chart
IFRX Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to IFRX. When comparing the yearly performance of all stocks, IFRX is a bad performer in the overall market: 68.67% of all stocks are doing better.
IFRX Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to IFRX. Both the profitability and financial health of IFRX have multiple concerns.
IFRX Earnings
On March 19, 2026 IFRX reported an EPS of -0.15 and a revenue of -34.00K. The company beat EPS expectations (1.96% surprise) and missed revenue expectations (-128.81% surprise).
IFRX Forecast & Estimates
14 analysts have analysed IFRX and the average price target is 9.03 USD. This implies a price increase of 834.06% is expected in the next year compared to the current price of 0.9672.
For the next year, analysts expect an EPS growth of -3.52% and a revenue growth 1221.94% for IFRX
IFRX Groups
Sector & Classification
IFRX Financial Highlights
Over the last trailing twelve months IFRX reported a non-GAAP Earnings per Share(EPS) of -0.77. The EPS increased by 15.19% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -61.55% | ||
| ROE | -88.4% | ||
| Debt/Equity | 0.02 |
IFRX Ownership
IFRX Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 13.91 | 364.897B | ||
| AMGN | AMGEN INC | 14.9 | 183.284B | ||
| GILD | GILEAD SCIENCES INC | 15.7 | 172.309B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 22.28 | 109.705B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.26 | 80.376B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 42.82 | 42.375B | ||
| INSM | INSMED INC | N/A | 35.141B | ||
| NTRA | NATERA INC | N/A | 29.66B | ||
| BIIB | BIOGEN INC | 10.92 | 25.773B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.94 | 24.795B | ||
| MRNA | MODERNA INC | N/A | 19.79B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 19.082B | ||
| INCY | INCYTE CORP | 12.23 | 18.645B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About IFRX
Company Profile
InflaRx NV is a clinical-stage biopharmaceutical company, which engages in the discovery and development of inhibitors of the complement activation factor known as C5a and its receptor C5aR. The company is headquartered in Jena, Thueringen and currently employs 74 full-time employees. The company went IPO on 2017-11-08. The firm's primary focus is on the development of monoclonal antibodies targeting activation products of the complement system for application in the treatment of life-threatening inflammatory diseases. Its lead product candidate, IFX-1, is an intravenously delivered first-in-class anti-C5a monoclonal antibody, undergoing Phase II clinical trial for the treatment of Hidradenitis Suppurativa (HS), a rare and chronic debilitating systemic inflammatory skin disease, and entering Phase II clinical trial for the treatment of ANCA-associated vasculitis (AAV) and other rare autoimmune diseases. The firm's product pipeline also includes IFX-2, which is in preclinical development.
Company Info
IPO: 2017-11-08
INFLARX NV
Winzerlaer Str. 2
Jena THUERINGEN 07745 DE
CEO: Niels Riedemann
Employees: 74
Phone: 493641508180
INFLARX NV / IFRX FAQ
Can you describe the business of INFLARX NV?
InflaRx NV is a clinical-stage biopharmaceutical company, which engages in the discovery and development of inhibitors of the complement activation factor known as C5a and its receptor C5aR. The company is headquartered in Jena, Thueringen and currently employs 74 full-time employees. The company went IPO on 2017-11-08. The firm's primary focus is on the development of monoclonal antibodies targeting activation products of the complement system for application in the treatment of life-threatening inflammatory diseases. Its lead product candidate, IFX-1, is an intravenously delivered first-in-class anti-C5a monoclonal antibody, undergoing Phase II clinical trial for the treatment of Hidradenitis Suppurativa (HS), a rare and chronic debilitating systemic inflammatory skin disease, and entering Phase II clinical trial for the treatment of ANCA-associated vasculitis (AAV) and other rare autoimmune diseases. The firm's product pipeline also includes IFX-2, which is in preclinical development.
What is the stock price of INFLARX NV today?
The current stock price of IFRX is 0.9672 USD. The price increased by 2.52% in the last trading session.
Does IFRX stock pay dividends?
IFRX does not pay a dividend.
What is the ChartMill technical and fundamental rating of IFRX stock?
IFRX has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Can you provide the sector and industry classification for INFLARX NV?
INFLARX NV (IFRX) operates in the Health Care sector and the Biotechnology industry.
Can you provide the PE ratio for IFRX stock?
INFLARX NV (IFRX) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.77).